Skip to main content

Table 1 Baseline characteristics

From: A novel risk model for mortality and hospitalization following cardiac resynchronization therapy in patients with non-ischemic cardiomyopathy: the alpha-score

VariablesOverall
N = 422
Patients with primary endpoint events
N = 333
Patients without primary endpoint events
N = 89
P-value
Age, y59 ± 1159 ± 1158 ± 120.989
Male, n (%)273(64.7)208(62.5)65(73.0)0.064
CRT-D, n (%)183(43.4)138(41.4)45(50.6)0.123
BMI, (kg/m2)24.53 ± 4.7124.85 ± 4.932323 ± 3.460.006
Atrial fibrillation, n (%)71(16.8)50(15.0)21(23.6)0.055
LBBB, n (%)297(70.4)250(75.1)47(52.8)< 0.001
NYHA class, n (%)
 II128(30.3)113(33.9)15(16.9)0.002
 III239(56.6)187(56.2)52(58.4)0.701
 IV55(13)33(9.9)22(24.7)< 0.001
 Initial QRS width(ms)166.92 ± 22.58164.43 ± 23.44168.81 ± 19.030.065
Echocardiography
 LA(mm)44.14 ± 7.4143.38 ± 7.1947.00 ± 7.54< 0.001
 LVEDD(mm)70.09 ± 10.6969.34 ± 10.6272.91 ± 10.520.005
LVEF (%)30.45 ± 8.4530.95 ± 8.5328.60 ± 7.910.020
Laboratory factors
 NT-proBNP (pg/ml)2173 ± 20181912 ± 17983150 ± 2462< 0.001
 Uric Acid (umol/L)433.65 ± 130.00430.15 ± 124.65446.75 ± 148.350.285
 HsCRP(mg/L)2.79 ± 3.893.21 ± 3.485.67 ± 4.69< 0.001
 Creatinine(umol/L)90.98 ± 28.6988.65 ± 23.6699.68 ± 41.570.001
 Albumin42.13 ± 4.8742.62 ± 4.9440.31 ± 4.15< 0.001
 AST23.41 ± 11.8822.56 ± 10.9726.55 ± 14.420.005
 Big endothelin-10.55 ± 0.410.49 ± 0.370.78 ± 0.45< 0.001
Medications
 ACEI/ARB, n (%)330(78.2)273(82.0)57(64.0)< 0.001
 Beta-blockers, n (%)384(91)304(91.3)80(89.9)0.681
 Diuretics, n (%)396(93.8)313(94.0)83(93.3)0.798
 Spironolactone, n (%)373(88.4)299(89.8)74(83.1)0.082
  1. CRT-D cardiac resynchronization therapy with a defibrillator, BMI Body mass index, LBBB Left bundle branch block, RBBB Right bundle branch block, NYHA The New York Heart Association Functional Classification, LA Left atrial dimeters, LVEDD Left ventricular end diastolic diameter, LVEF Left ventricular ejection fraction, NT-proBNP N-terminal pro-B-type natriuretic peptide, HsCRP High-sensitivity C-reactive protein, LDL-C Low density lipoprotein cholesterol, HDL-C High density lipoprotein cholesterol, AST Aspartate aminotransferase, ACEI Angiotensin converting enzyme inhibitor, ARB Angiotensin receptor blockers; P-value:Comparison between derivation cohort and validation cohort